This same dysregulation of AS profiles in MS cases, characterized by the loss of genotype-dependent splicing in the presence of a polymorphism directly affecting a splice site, has been already described for at least two other genes (PRKCA and NFAT5) [11,12], thus possibly representing a specific “signature” of the disease status. The gene discussed is NFAT5; the disease is myeloid sarcoma.